As with prior adjuvant trials, RELATIVITY-098 (NCT05002569) a phase 3 trial comparing combination relatlimab (anti-LAG-3) and nivolumab to nivolumab alone in the adjuvant setting utilizes stage IIIA with at least 1 mm nodal tumor deposit as the threshold for inclusion. Here, LAG3 is linked to neoplasm.